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ABSTRACT
Although the prognostic effect of obesity has been studied in critically ill patients its impact on
outcomes of septic patients and its role as a risk factor for acute kidney injury (AKI) is not con-
sensual. We aimed to analyze the impact of obesity on the occurrence of AKI and on in-hospital
mortality in a cohort of critically ill septic patients. This study is retrospective including 456 adult
patients with sepsis admitted to the Division of Intensive Medicine of the Centro Hospitalar
Lisboa Norte (Lisbon, Portugal) between January 2008 and December 2014. Obesity was defined
as a body mass index of 30 kg/m2 or higher. The Kidney Disease Improving Global Outcomes
classification was used to diagnose and classify patients developing AKI. AKI occurred in 87.5% of
patients (19.5% with stage 1, 22.6% with stage 2 and 45.4% with stage 3). Obese patients devel-
oped AKI more frequently than non-obese patients (92.8% versus 85.5%, p¼ .035; unadjusted OR
2.2 (95% CI: 1.04–4.6), p¼ .039; adjusted OR 2.31 (95% CI: 1.07–5.02), p¼ .034). The percentage of
obese patients, however, did not differ between AKI stages (stage 1, 25.1%; stage 2, 28.6%; stage
3, 15.4%; p¼ .145). There was no association between obesity and mortality (p¼ .739). Of note,
when comparing AKI patients with or without obesity in terms of in-hospital mortality there were
also no significant differences between those groups (38.4% versus 38.4%, p¼ .998). Obesity was
associated with the occurrence of AKI in critically ill patients with sepsis; however, it was not
associated with in-hospital mortality.
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Obesity is considered as a major public health problem
and has been shown to be associated with an increased
all-cause mortality, cardiovascular disease (CVD) and
diabetes mellitus [1]. The high prevalence of obesity in
the general population has led to a higher number of
obese patients being hospitalized in the intensive care
unit (ICU). Although the prognostic effect of obesity has
been extensively studied in critically ill patients [2,3],
the impact of obesity on outcomes of patients with sep-
sis is not well studied. In fact, the relationship between
obesity and sepsis mortality is inconsistent in the litera-
ture [1,4,5].
Obesity has also been associated with chronic kidney
disease (CKD) [6,7], however, its role as a risk factor for
acute kidney injury (AKI) is still not consensual [8,9].
The foremost cause of AKI in the ICU is sepsis and
patients with non-septic AKI are clinically different from
those suffering from AKI of septic origin. In actual fact,
septic AKI is associated with higher disease severity
scores at admission into the ICU, requirement of vaso-
active drugs, need for mechanical ventilation, non-renal
organ failure, prolonged lengths of ICU and hospital
stay, increased in-hospital mortality and a higher prob-
ability of recovery of renal function at the time of dis-
charge from hospital [10,11]. Subsequently, the need
for a profound understanding and purview of septic AKI
by the nephrologist and the intensivist is indispensable
as a means to ensure adequate diagnoses, treatment
decisions, follow-up strategies and, ultimately, predict-
ing patient outcome.
The aim of this study was to analyze the impact of
obesity on the occurrence of AKI and on in-hospital
mortality in a cohort of critically ill patients admitted
with sepsis. For this purpose, we cross-examined data
from a retrospective study in which we studied a cohort
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of critically ill patients admitted with sepsis to the ICU
in which the objective was to compare the diagnostic
sensitivity and prognostic ability of the standard classifi-
cations for AKI, namely the ‘Risk, Injury, Failure, Loss of
kidney function, End-stage kidney disease’, Acute
Kidney Injury Network and Kidney Disease: Improving
Global Outcomes (KDIGO) classifications [12]. We per-
formed a similar analysis from this data to study the
association of serum lactates and AKI [13].
Materials and methods
This is a retrospective study including all patients with
sepsis admitted to the Division of Intensive Medicine of
the Centro Hospitalar Lisboa Norte (Lisbon, Portugal),
an academic and referral center covering 3,000,000
inhabitants, between January 2008 and December 2014.
The study was approved by the Ethical Committee at
the Centro Hospitalar Lisboa Norte, EPE, in agreement
with institutional guidelines. Informed consent was
waived by the Ethical Committee due to the retrospect-
ive and non-interventional nature of the study.
Participants
Eligible patients were selected according to the ICU
patient admission register as adult patients (18 years
of age) with a diagnosis of sepsis or septic shock at
admission to the Division of Intensive Medicine. The
third international consensus definitions for sepsis and
septic shock were used [14]. Exclusion criteria were
defined and comprised (i) CKD patients on renal
replacement therapy, (ii) patients who underwent renal
replacement therapy 1 week prior to admission to the
ICU and (iii) patients who were discharged or died less
than 2 d after ICU admission.
Variables and data sources
All patient variables were collected from individual clin-
ical records. We analyzed the following variables: patient
demographic characteristics (age, gender, ethnicity, body
weight and height), comorbidities (presence of diabetes
mellitus, hypertension, chronic obstructive pulmonary
disease (COPD), CVD, cirrhosis and/or malignancy), pri-
mary diagnosis on admission (medical versus surgical in
nature), source of infection, serum hemoglobin, serum
albumin, serum creatinine (SCr), urine output (UO), dis-
ease severity according to the Simplified Acute
Physiologic Score (SAPS) II [15] as determined by the
worst variables recorded during the first 24 h, fluid bal-
ance, mechanical ventilation, vasopressor use and
requirement for renal replacement therapy. Diabetes
mellitus was diagnosed according to the American
Diabetes Association criteria [16] and hypertension was
diagnosed according to the seventh report of the Joint
National Committee [17]. COPD included emphysema
and chronic bronchitis and CVD was considered as pre-
sent whenever a history of cerebrovascular disease,
chronic heart failure of any cause, cardiac ischemic dis-
ease and/or peripheral arterial disease was documented,
also, a previous diagnosis on clinical records was consid-
ered sufficient for the confirmation of this diagnosis. The
outcomes measured were AKI and in-hospital mortality.
Obesity was defined as a body mass index (BMI) of
30 kg/m2 or higher, and underweight was defined as a
BMI lower than 18.5 kg/m2 [18].
AKI was diagnosed within the first week of ICU hospi-
talization based on the KDIGO classification according to
both SCr and UO criteria (Table 1). In this ICU, the proto-
col for all patients includes daily determination of SCr
and hourly UO. Pre-admission SCr (SCr within the previ-
ous 3 months) were considered as baseline values. When
these values were unavailable, baseline SCr was estimated
from the modification of diet in renal disease (MDRD)
equation [19], accepting the lower limit of a normal base-
line glomerular filtration rate (GFR) of 75ml/min/1.73 m2.
Statistical methods
Categorical variables were described as the total num-
ber and percentage for each category, whereas continu-
ous variables were described as the mean± standard
deviation. Normally distributed continuous variables
were compared with the Student’s t-test, non-normally
distributed continuous variables were compared with
the Mann–Whitney U test and categorical variables
were compared with the chi-square test. To determine
risk factors for AKI and for in-hospital mortality, univari-
ate and multivariate logistic regression analysis was
employed. In the multivariate analysis (enter model),
only variables with statistical significance in the univari-
ate analysis were included. Data were expressed as
odds ratios (ORs) with 95% confidence intervals (CIs).
Additionally, a sensitivity analysis excluding under-
weight patients was performed to eliminate the poten-
tial confound of this variable on the occurrence of AKI
and in mortality. Statistical significance was defined as a
Table 1. Kidney disease improving global outcomes (KDIGO)
classification.
Stage SCr/GFR UO
1 " SCr 26.5lmol/l (0.3mg/dl)
or " SCr 150–200% (1.5–1.9X)
<0.5ml/kg/h (>6 h)
2 " SCr >200–300% (>2–2.9X) <0.5ml/kg/h (>12 h)
3 " SCr >300% (3X)
or " SCr to 353.6 lmol/l (4mg/dl)
or initiation of renal replacement therapy
<0.3ml/kg/h (24 h)
or anuria (12 h)
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p value <.05. Statistical analysis was performed with the
statistical software package SPSS for Windows (version
21.0; SPSS, Chicago, IL).
Results
Participants
Of the 722 potentially eligible patients, 266 were
excluded based on the following reasons: 122 had stage
5 CKD on renal replacement therapy and 144 had been
hospitalized for less than 48 h. No patients required
renal replacement therapy in the week preceding ICU
admission. Accordingly, we studied a final cohort of
456 patients. Baseline characteristics are described in
Table 2, while clinical and demographic characteristics
of the studied patients according to AKI and obesity are
shown in Tables 3 and 4.
Obese patients were more likely to be female
(p¼ .016) and Caucasian (p¼ .011), and, as expected, to
have prior hypertension (p¼ .007) and diabetes
(p¼ .003). Furthermore, neoplasia (p¼ .001) and respira-
tory origin (p¼ .013) were less frequent in obese
patients. Obese patients had higher SAPS II values
(p¼ .043) and hemoglobin (p¼ .005) at ICU admission.
Pre-admission SCr was available in 185 patients
(40.6%) and in the remaining cases [n¼ 272 (59.4%)]
Table 2. Patients’ baseline characteristics.
Characteristics Value
Age (year) 64.1 ± 16.4
Gender (Male) – n (%) 264 (57.9)
Race (Caucasian) – n (%) 433 (94.7)
Obese (IMC>¼30) – n (%) 125 (27.4)
Underweight (IMC <18.5) – n (%) 9 (2)
Hypertension – n (%) 212 (46.5)






Medical admission – n (%) 253 (55.5)







SAPS II 49.4 ± 17.3
Baseline SCr (mg/dl) 1.3 ± 0.6
Admission SCr (mg/dl) 2.3 ± 1.5
Hemoglobin (g/dl) 10.4 ± 2.0
Serum albumin (g/dl) 1.9 ± 0.6
Mechanical ventilation – n (%) 350 (76.8)
Vasopressors – n (%) 316 (369.3)
Fluid balance (l) 4.5 ± 5.7
RRT – n (%) 108 (23.7)
LOS in hospital (days) 37.1 ± 39.4
LOS in ICU (days) 10.0 ± 10.0
ICU mortality – n (%) 108 (23.7)
In-hospital mortality – n (%) 153 (33.6)
Table 3. Demographic and clinical characteristics of patients
according to the development of acute kidney injury defined
by the KDIGO classification.
KDIGO
Characteristics No AKI (n¼ 57) AKI (n¼ 399) p Value
Age (year) 64.1 ± 17.4 64.1 ± 16.0 .994
Gender (Male) – n (%) 35 (61.4) 229 (57.4) .566
Race (Caucasian) – n (%) 54 (94.7) 379 (95.0) .936
Obesity – n (%) 9 (15.7) 116 (29.1) .035
Underweight – n (%) 3 (5.3) 6 (1.5) .242
Co-morbidities – n (%)
Hypertension 30 (50.2) 182 (45.6) .320
Diabetes 15 (26.3) 88 (22.1) .472
CVD 14 (24.6) 111 (27.8) .606
COPD 5 (8.8) 33 (8.3) .898
Cirrhosis 1 (1.8) 17 (4.3) .363
Neoplasia 13 (22.8) 96 (24.1) .836
Medical admission – n (%) 31 (54.4) 222 (55.6) .859
Infection source – n (%)
Abdominal 19 (33.3) 168 (42.1) .208
Respiratory 16 (28.3) 122 (30.6) .700
Kidney 14 (24.6) 43 (10.8) .003
Skin 2 (3.5) 32 (8.0) .225
Others 6 (10.5) 20 (5.0) .093
Unknown 0 (0.0) 14 (3.5) .151
SAPS II 42.8 ± 15.6 50.4 ± 17.3 .002
Baseline SCr (mg/dl) 1.4 ± 0.7 1.3 ± 0.6 .185
Hemoglobin (g/dl) 10.0 ± 1.7 10.5 ± 2.0 .078
Serum albumin (g/dl) 2.1 ± 0.6 1.9 ± 0.6 .003
Mechanical ventilation – n (%) 41 (71.9) 309 (77.4) .357
Vasopressors – n (%) 26 (45.6) 290 (72.7) <.001
RRT – n (%) 108 (27.1)
LOS in hospital (days) 39.5 ± 44.8 36.7 ± 38.6 .625
LOS in ICU (days) 9.8 ± 10.3 10.0 ± 10.0 .881
ICU mortality – n (%) 7 (12.3) 101 (25.3) .030
Hospital mortality – n (%) 10 (17.5) 143 (87.5) .006








(n¼ 125) p Value
Age (year) 63.9 ± 16.5 64.4 ± 14.8 .779
Gender (Male) – n (%) 203 (61.3) 61 (48.8) .016
Race (Caucasian) – n (%) 309 (93.4) 124 (99.2) .011
AKI – n (%) 283 (85.5) 116 (92.8) .035
Comorbidities – n (%)
Hypertension 141 (43) 71 (56.8) .007
Diabetes 63 (19) 40 (32) .003
CVD 98 (29.6) 27 (21.6) .087
COPD 32 (9.7) 6 (4.8) .093
Cirrhosis 12 (3.6) 6 (4.8) .566
Neoplasia 93 (28.1) 16 (12.8) .001
Medical admission – n (%) 188 (56.8) 65 (52) .398
Infection source – n (%)
Abdominal 132 (56.8) 55 (44) .425
Respiratory 111 (33.5) 27 (21.6) .013
Kidney 37 (11.2) 20 (16) .165
Skin 25 (7.6) 9 (7.2) .898
Others 18 (5.4) 8 (6.4) .693
Unknown 8 (2.4) 6 (4.8) .188
SAPS II 48.4 ± 17.3 52.1 ± 17.1 .043
Baseline SCr (mg/dl) 1.3 ± 0.58 1.3 ± 0.67 .524
Hemoglobin (g/dl) 10.2 ± 2 10.8 ± 2 .005
Serum albumin (g/dl) 1.9 ± 0.6 1.9 ± 0.5 .896
Mechanical ventilation – n (%) 256 (77.3) 94 (75.2) .629
Vasopressors – n (%) 228 (68.9) 88 (70.4) .754
RRT – n (%) 64 (19.3) 44 (35.2) <.001
LOS in hospital (days) 38.8 ± 39.3 32.6 ± 39.3 .136
LOS in ICU (days) 10 ± 9.8 10 ± 10.7 .91
ICU mortality – n (%) 81 (24.5) 27 (21.6) .520
Hospital mortality – n (%) 113 (34.1) 40 (32) .666
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estimation using the MDRD formula was necessary. AKI
occurred in 87.5% of patients with a maximum KDIGO
category (19.5% with stage 1, 22.6% with stage 2 and
45.4% with stage 3). One-hundred and eight patients
(23.7%) underwent renal replacement therapy (8.3%
intermittent hemodialysis, 76% HDFVVC, and 15.7%
both). AKI developed more frequently in patients with
urinary tract infections (p¼ .003), with higher SAPS II
values (p¼ .002) and lower albumin values (p¼ .003).
Also, AKI patients were more likely to require vasopres-
sors (p< .001).
Obesity and AKI
Obese patients developed AKI more frequently than
non-obese patients (92.8% versus 85.5%, p¼ .035;
unadjusted OR 2.2 (95% CI: 1.04–4.6), p¼ .039; adjusted
OR 2.31 (95% CI: 1.07–5.02), p¼ .034). The percentage
of obese patients, however, did not differ between AKI
stages (stage 1, 25.1%; stage 2, 28.6%; stage 3, 15.4%;
p¼ .145) (Tables 3, 4 and 6). After excluding under-
weight patients, obesity still remained associated with
AKI (92.8% versus 85.1%, p¼ .028; unadjusted OR 2.2
(95% CI: 0.015–0.264), p¼ .028; adjusted OR 2.3 (95% CI:
0.011–0.146), p¼ .024).
Obese patients developing AKI were more likely to
require renal replacement therapy than non-obese AKI
patients (37.9% versus 22.6%, p< .001).
Obesity and in-hospital mortality
There was no association between obesity and mortality
(p¼ .739) (Tables 4–6). After excluding underweight
Table 5. Demographic and clinical characteristics of patients





mortality 153 p Value
Age (year) 62.32 ± 15.9 67.54 ± 15.8 .001
Gender (Male) – n (%) 171 (56.4) 93 (60.8) .374
Race (Caucasian) – n (%) 290 (95.7) 143 (93.5) .301
Obesity – n (%) 85 (28.1) 40 (26.1) .739
Comorbidities – n (%)
Hypertension 144 (47.5) 68 (44.4) .533
Diabetes 69 (22.8) 34 (22.2) .894
CVD 85 (28.1) 40 (26.1) .666
COPD 21 (6.9) 17 (11.1) .127
Cirrhosis 11 (3.6) 7 (4.6) .625
Neoplasia 59 (19.5) 50 (32.7) .002
Medical admission – n (%) 168 (55.4) 85 (55.6) .982
Infection source – n (%)
Abdominal 120 (39.6) 67 (43.8) .391
Respiratory 90 (29.7) 48 (31.4) .714
Kidney 47 (15.5) 10 (6.5) .006
Skin 21 (5.9) 13 (8.5) .574
Others 17 (5.6) 9 (6) 1.000
Unknown 8 (2.6) 6 (3.9) .566
SAPS II 45.13 ± 15.4 57.94 ± 16.7 <.001
Baseline SCr (mg/dl) 1.3 ± 0.64 1.25 ± 0.54 .47
Hemoglobin (g/dl) 10.7 ± 2 9.9 ± 2 <.001
Serum albumin (g/dl) 1.98 ± 0.57 1.79 ± 0.6 .002
Mechanical ventilation – n (%) 215 (71) 135 (88.2) <.001
Vasopressors – n (%) 193 (63.7) 123 (80.4) <.001
RRT – n (%) 43 (14.2) 65 (42.5) <.001
AKI – n (%) 256 (84.5) 143 (93.5) .006
LOS in hospital (days) 37.97 ± 38 35.3 ± 41.9 .494
LOS in ICU (days) 9.6 ± 9.6 10.7 ± 10.9 .261
Table 6. Univariate and multivariate analysis of factors predictive of outcomes.
AKI Mortality
Unadjusted
HR (95% CI) p Value
Adjusted
HR (95% CI) p Value
Unadjusted
HR (95% CI) p Value
Adjusted
HR (95% CI) p Value
Demographics
Age 1.00 (0.98–1.02) .094 1.02 (1.08–1.04) .001 1.02 (1.00–1.03) .026
Male 0.85 (0.48–1.50) .567 1.20 (0.81–1.18) .375
Caucasian 1.053 (0.30–3.66) .936 0.64 (0.27–1.50) .304
Obesity 2.19 (1.04–4.60) .039 2.31 (1.07–5.02) .034 0.91 (0.59–1.41) .666
Underweight 1.2 (0.29–0.07) .243 0.38 (0.2–0.31) .704
Comorbidities
Hypertension 0.76 (0.43–1.32) .321 0.88 (0.60–1.31) .534
Diabetes 0.79 (0.42–1.50) .473 0.97 (0.61–1.54) .894
CVD 1.18 (0.62–2.25) .606 0.91 (0.59–1.41) .666
COPD 0.94 (0.35–2.51) .898 1.68 (0.86–3.29) .131
Cirrhosis 2.492 (0.33–19.09) .379 1.27 (0.48–3.35) .625
Neoplasia 1.04 (0.75–1.44) .836 1.42 (1.14–1.77) .002 1.2 (0.93–1.55) .166
Medical admission 1.05 (0.60–1.84) .859 1.00 (0.68–1.49) .982
Infection source
Abdominal 1.45 (0.81–2.61) .210 1.18 (0.80–1.76) .391
Respiratory 1.13 (0.61–2.09) .700 1.08 (0.71–1.65) .714
Kidney 0.37 (0.19–0.73) .004 0.39 (0.19–0.82) .013 0.38 (0.19–0.78) .008 0.40 (0.17–0.93) .034
Skin 2.40 (0.56–10.29) .239 1.25 (0.61–2.56) .548
Others 0.45 (0.17–1.17 .101 1.05 (0.46–2.42) .906
SAPS II 1.03 (1.01–1.05) .002 1.01 (0.99–1.03) .187 1.05 (1.04–1.06) .000 1.04 (1.02–1.06) .000
Baseline SCr 0.76 (0.50–1.15) .188 0.89 (0.64–1.23) .469
Hemoglobin 1.14 (0.99–1.32) .078 0.80 (0.72–0.89) .000 0.79 (0.70–0.89) .000
Serum albumin 0.51 (0.33–0.81) .004 0.67 (0.41–1.09) .105 0.56 (0.39–0.81) .002 0.91 (0.60–1.39) .661
Mechanical ventilation 1.34 (0.72–2.50) .358 3.07 (1.77–5.33) .000 1.78 (0.94–3.40) .079
Vasopressors 3.17 (1.80–5.59) .000 2.63 (1.37–5.04) .004 2.34 (1.47–3.71) .000 1.1 (0.62–1.94) .749
AKI 2.63 (1.29–5.35) .008 2.44 (1.07–5.57) .035
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patients, the same findings were observed (32% versus
33.9%, p¼ .709; unadjusted OR 0.4 (95% CI:
0.12–0.08), p¼ .71). Of note, when comparing AKI
patients with or without obesity in terms of in-hospital
mortality there were also no significant differences
between those groups (32% versus 34.1%, p¼ .666).
Discussion
To our knowledge, this is the first study aiming to evalu-
ate the association between obesity and AKI in septic
patients and its impact in mortality. In this retrospective
study including 456 critically ill patients with sepsis, we
found that obesity was independently associated with
AKI, increasing the risk for developing AKI.
Our results are in line with other studies which estab-
lished an association between obesity and risk of AKI in
critically ill patients or in post-operative patients. In a
study by Danzinger et al., in a population of 14,986 crit-
ically ill patients admitted to a medical or surgical ICU,
obese patients developed more AKI [20]. Thakar et al.
noted a prevalence of AKI of 8.5% regarding 491
patients submitted to bariatric surgery and described its
impact in prolonging the length of hospital stay [21].
Yap et al. found that obesity and morbid obesity were
associated with an increased risk for AKI [22]. Billings
et al. reported BMI as an independent risk factor for the
development of AKI in a population of 112 patients
after cardiac surgery [23]. Kumar et al. detailed an
increased risk for AKI in patients with BMI> 40 kg/m2 in
376 patients who underwent cardiac surgery [24] Soto
et al. demonstrated that an increasing BMI was signifi-
cantly associated with development of AKI in a cohort
of 715 patients with Acute Respiratory Distress
Syndrome [25]. Plataki et al. demonstrated that BMI was
independently associated with AKI in ICU patients with
septic shock [26].
Obesity dramatically alters renal hemodynamics,
which could explain an increased susceptibility to AKI in
obese patients [27]. Although the pathophysiology is
not completely understood, the increased renal plasma
flow and GFR resulting from altered hemodynamics
could lead to a higher filtration fraction or hyperfiltra-
tion syndrome, potentially contributing to an increased
renal susceptibility to damage [28]. A recent study by
Billings et al. found that markers of oxidative stress
appear to affect renal function by reducing renal perfu-
sion, reducing creatinine clearance, and instigating cel-
lular and functional renal damage in experimental
models, and demonstrated that these biomarkers were
a strong predictor of AKI in cardiac surgery patients
[23]. Adipose production of inflammatory mediators, as
well as adipokines such as leptin, and decreased
production of adiponectin, in response to acute illness
have been associated with a heightened AKI risk [29].
Another factor that could contribute to obesity’s influ-
ence on AKI is the challenge to correctly assess the
intravascular volume status and to prescribe adequate
fluid therapy and/or vasopressors. Dosing of potentially
nephrotoxic agents may also be demanding, since
obesity impacts many pharmacokinetic factors, and the
dose itself may be variable depending on whether it
was based on actual body weight or on formulae-based
weight adjustment, not obesity [30]. Notably, obese ICU
patients are at an increased risk for elevated intra-
abdominal pressure, which may, in itself, cause renal
dysfunction from both venous congestion and poor
arterial organ perfusion [31,32].
Cardiac changes associated with obesity, such as
increased left ventricular hypertrophy and direct infiltra-
tion of the myocardium might also alter renal perfusion
[33]. Consequently, it is plausible that kidney and/or car-
diac-specific changes associated with obesity contribute
to the prevalence of AKI.
Although not the scope of this study, our results also
confirmed an association between AKI and mortality in
septic patients (93.5% versus 84.5%, p¼ .006;
unadjusted OR 2.63 (95% CI: 1.29–5.35), p¼ .008;
adjusted OR 2.44 (95% CI: 1.07–5.57), p¼ .035), which is
in accordance with previously published studies of AKI
in the critically ill patient [34,35].
The impact of obesity on mortality in septic patients
still remains unclear. Our results are in concordance with
other studies that did not demonstrate any relationship
between obesity and mortality in septic patients. Sakr
et al. performed a sub-study based on the observational
sepsis occurrence in acutely ill patients (SOAP) study,
enrolling 198 ICUs in 24 European countries and did not
find any statistically significant association between
obesity and sepsis mortality [5]. Similar findings were
described by Chalkias et al. in a small prospective cohort
study [6]. Remarkably, in a study by Nguyen et al. obes-
ity was associated with a significant decrease in mortal-
ity among hospitalized septic patients; nevertheless, it
was also associated with greater duration and cost of
hospitalization [36]. Prescott et al. also reported that
obesity was independently associated with decreased
mortality up to 1 year after hospitalization in an observa-
tional study of 1404 severe sepsis patients [37]. On con-
trary, Huttunen et al. reported a higher risk of death in
obese patients with sepsis [38].
The term ‘obesity paradox’ has been used to describe
similar or improved survival for obese critically ill
patients notwithstanding concomitant comorbidities.
One explanation proposed for this phenomenon is that
obese patients benefit from a metabolic or nutritional
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reserve, which ultimately culminates in an increased
survival in conditions of illness [39]. Another hypothesis
is that there is an underlying difference in metabolic
and immune responses to acute illness which may act
as a counterbalance to excess inflammation [40,41].
However, another plausible justification is the presence
of methodological issues observed in the aforemen-
tioned studies.
In the present study, some limitations have to be
acknowledged. First, the single-center and retrospective
nature of the study with a small cohort of patients may
compromise, at least in part, the results of our study.
Second, although hourly UO measurements were avail-
able to us for collection and analysis, data regarding add-
itional factors that could potentially influence UO, such
as the use of diuretic therapy, was not. Third, the pre-
admission SCr level was unknown in nearly 60% of
patients, compelling us to calculate an estimated base-
line function using the MDRD equation, albeit as recom-
mended (assuming the lower limit of the normal
baseline GFR 75ml/min/1.73m2). In addition, it addresses
only all-cause mortality and not cause-specific mortality
or morbidity, and it also addresses only findings related
to BMI and not to other aspects of body composition,
such as visceral fat or fat distribution. Lastly, the patho-
physiologic mechanisms on the association between
obesity and AKI were not examined.
Despite these limitations, our study has several note-
worthy strengths. To the best of our knowledge, this is
the first study evaluating the association between obes-
ity and AKI and between obesity and in-hospital mortal-
ity in septic patients in an ICU. Additionally, we used
not only creatinine criteria but also UO criteria to diag-
nose and categorize AKI. Finally, despite the retrospect-
ive nature of the study, most of the studied variables
were registered as part of routine clinical practice on a
daily basis and made accessible for analysis.
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